8th Apr 2013 16:08
Epistem Plc ("Epistem" or the "Company")
Directors' Shareholdings
Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 195 ordinary shares of 1.5p each. These shares were acquired on 28th January 2013, 25th February 2013 and 25th March 2013 at prices of 556p, 554p and 556p respectively.
Following these transactions, the current beneficial interests of the executive Directors are set out below:
Ordinary Shares %
Matthew Walls 10,174 0.11%
Dr Catherine Booth 984,529 10.19%
Dr Jeffrey Moore 13,854 0.14%
John Rylands 194,427 2.01%
Epistem further announces that it was informed on 5th April 2013 that, on that day, Dr Catherine Booth transferred 8,721 ordinary shares of 1.5 pence each to her Self Invested Personal Pension fund at a price of 550p Following this transaction, Dr. Catherine Booth's beneficial interest remains unchanged at 984,529 ordinary shares representing 10.19% of the Company's issued share capital.
For further details please contact:
Epistem Plc
Matthew Walls, CEO +44 161 606 7258
John Rylands, Finance Director +44 161 606 7244
Peel Hunt LLP
James Steel /Vijay Barathan +44 20 7418 8900
Related Shares:
Genedrive